PTC Therapeutics Inc
XBER:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
XBER:BH3
|
US |
|
Orrstown Financial Services Inc
F:OFR
|
US |
|
Sasol Ltd
OTC:SASOF
|
ZA |
|
Stadio Holdings Ltd
F:0JX
|
ZA |
|
Star Diamond Corp
TSX:DIAM
|
CA |
|
E
|
electroCore, Inc.
XBER:43E
|
US |
|
Amplitude Energy Ltd
F:CDP0
|
AU |
|
B
|
BlackBerry Ltd
SWB:RI1
|
CA |
|
James Hardie Industries PLC
F:JHA1
|
IE |
Wall St Price Targets
BH3 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BH3 is 76.41 EUR with a low forecast of 52.72 EUR and a high forecast of 104.55 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BH3's stock price target?
Price Target
76.41
EUR
According to Wall Street analysts, the average 1-year price target for BH3 is 76.41 EUR with a low forecast of 52.72 EUR and a high forecast of 104.55 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 3 years is -2%.
What is the Gross Profit forecast for PTC Therapeutics Inc?
Projected CAGR
-5%
The compound annual growth rate for Gross Profit over the next 3 years is -5%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-12%
The compound annual growth rate for Operating Income over the next 3 years is -12%.
What is the Pre-Tax Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is -20%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-20%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 3 years is -20%.
